DK1718649T3 - Imidazo[1,2-c]pyrimidinyleddikesyrederivater - Google Patents

Imidazo[1,2-c]pyrimidinyleddikesyrederivater

Info

Publication number
DK1718649T3
DK1718649T3 DK05706922T DK05706922T DK1718649T3 DK 1718649 T3 DK1718649 T3 DK 1718649T3 DK 05706922 T DK05706922 T DK 05706922T DK 05706922 T DK05706922 T DK 05706922T DK 1718649 T3 DK1718649 T3 DK 1718649T3
Authority
DK
Denmark
Prior art keywords
diseases
imidazo
allergic
acid derivative
treatment
Prior art date
Application number
DK05706922T
Other languages
Danish (da)
English (en)
Inventor
Kevin B Bacon
Klaus Urbahns
Takuya Shintani
Tai-Wei Ly
Takashi Yoshino
Yuki Takekawa
Hiromi Sugimoto
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1718649T3 publication Critical patent/DK1718649T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK05706922T 2004-01-31 2005-01-19 Imidazo[1,2-c]pyrimidinyleddikesyrederivater DK1718649T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002144 2004-01-31
PCT/EP2005/000475 WO2005073234A2 (en) 2004-01-31 2005-01-19 Imidazo[1,2-c]pyrimidinylacetic acid derivatives

Publications (1)

Publication Number Publication Date
DK1718649T3 true DK1718649T3 (da) 2009-08-24

Family

ID=34814234

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05706922T DK1718649T3 (da) 2004-01-31 2005-01-19 Imidazo[1,2-c]pyrimidinyleddikesyrederivater

Country Status (24)

Country Link
US (1) US7750014B2 (sl)
EP (1) EP1718649B1 (sl)
JP (1) JP4996257B2 (sl)
KR (1) KR101207428B1 (sl)
CN (1) CN100584844C (sl)
AT (1) ATE433452T1 (sl)
AU (1) AU2005209381B2 (sl)
BR (1) BRPI0507123A (sl)
CA (1) CA2551778C (sl)
CY (1) CY1109274T1 (sl)
DE (1) DE602005014849D1 (sl)
DK (1) DK1718649T3 (sl)
ES (1) ES2326896T3 (sl)
HK (1) HK1101969A1 (sl)
IL (1) IL177083A (sl)
MX (1) MXPA06007674A (sl)
NO (1) NO20063878L (sl)
NZ (1) NZ548396A (sl)
PL (1) PL1718649T3 (sl)
PT (1) PT1718649E (sl)
RU (1) RU2373208C2 (sl)
SI (1) SI1718649T1 (sl)
WO (1) WO2005073234A2 (sl)
ZA (1) ZA200605387B (sl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1833791T3 (pl) 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
JP5220013B2 (ja) 2006-08-07 2013-06-26 アクテリオン ファーマシューティカルズ リミテッド （３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体
BRPI0810195A2 (pt) * 2007-04-13 2014-12-30 Novartis Ag Moduladores de gpbar1
CN103172572A (zh) * 2007-06-21 2013-06-26 艾克提麦斯医药品有限公司 Crth2 拮抗剂的微粒
JP5524847B2 (ja) * 2007-09-25 2014-06-18 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストとしてのアルキルチオピリミジン
US8314116B2 (en) * 2007-09-25 2012-11-20 Actimis Pharmaceuticals, Inc. 2-S-benzyl substituted pyrimidines as CRTH2 antagonists
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
JP5586606B2 (ja) * 2008-09-02 2014-09-10 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストとしての同位体富化されたピリミジン−５−イル酢酸誘導体
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
MA34094B1 (fr) 2010-03-22 2013-03-05 Actelion Pharmaceuticals Ltd Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
RU2013104506A (ru) 2010-07-05 2014-08-10 Актелион Фармасьютиклз Лтд 1-фенилзамещенные производные гетероциклила и их применение в качестве модуляторов рецептора простагландина d2
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010031149A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimidine und Triazine und ihre Verwendung
DE102011003315A1 (de) 2011-01-28 2012-08-02 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimindine und Triazine und ihre Verwendung
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
MX338516B (es) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
ES2624379T3 (es) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
EP2822951B1 (de) 2012-03-06 2017-07-26 Bayer Intellectual Property GmbH Substituierte azabicyclen und ihre verwendung
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
MY179356A (en) 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP3119780B1 (en) 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
MX2018003202A (es) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Formas cristalinas.
KR20190103507A (ko) 2018-02-12 2019-09-05 김강민 지하철 혼잡도 알림 시스템
TW202100015A (zh) 2019-02-28 2021-01-01 瑞士商先正達農作物保護公司 具有含硫取代基之殺有害生物活性雜環衍生物
CN114681438B (zh) * 2022-05-17 2024-03-19 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物在逆转Gal-10结晶趋势并缓解相关疾病中应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
MXPA05006701A (es) * 2002-12-20 2006-03-30 Amgen Inc Moduladores de asma y de inflacion alergica.
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2

Also Published As

Publication number Publication date
AU2005209381A1 (en) 2005-08-11
CA2551778A1 (en) 2005-08-11
US7750014B2 (en) 2010-07-06
WO2005073234A3 (en) 2005-10-06
KR20060130187A (ko) 2006-12-18
IL177083A (en) 2011-10-31
PT1718649E (pt) 2009-08-06
CN1938310A (zh) 2007-03-28
ZA200605387B (en) 2008-05-28
JP2007519659A (ja) 2007-07-19
DE602005014849D1 (de) 2009-07-23
RU2373208C2 (ru) 2009-11-20
CY1109274T1 (el) 2014-07-02
US20090012102A1 (en) 2009-01-08
MXPA06007674A (es) 2006-09-04
ATE433452T1 (de) 2009-06-15
HK1101969A1 (en) 2007-11-02
ES2326896T3 (es) 2009-10-21
WO2005073234A2 (en) 2005-08-11
CA2551778C (en) 2013-10-22
EP1718649B1 (en) 2009-06-10
IL177083A0 (en) 2006-12-10
JP4996257B2 (ja) 2012-08-08
SI1718649T1 (sl) 2009-10-31
BRPI0507123A (pt) 2007-06-19
EP1718649A2 (en) 2006-11-08
RU2006131304A (ru) 2008-03-10
AU2005209381B2 (en) 2011-06-30
NO20063878L (no) 2006-10-11
KR101207428B1 (ko) 2012-12-04
CN100584844C (zh) 2010-01-27
PL1718649T3 (pl) 2009-11-30
NZ548396A (en) 2010-06-25

Similar Documents

Publication Publication Date Title
DK1718649T3 (da) Imidazo[1,2-c]pyrimidinyleddikesyrederivater
TW200505873A (en) Pyrimidine derivatives
EP2380891B1 (de) Substituierte Piperidino-Dihydrothienopyrimidine
NO20052076L (no) Fuserte azol-pyrimidinderivater.
WO2004011427A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
WO2004010943A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
MXPA05010055A (es) Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos.
MY157615A (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
US20090137608A1 (en) Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
ATE424402T1 (de) Imidazopyridinverbindungen
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
CA2700524C (en) Alkylthio pyrimidines as crth2 antagonists
EA201170374A1 (ru) Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
WO2004010942A3 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
JP2015517587A5 (sl)
TW200631954A (en) New pyridothienopyrimidine derivatives
DE602006016244D1 (de) Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
Xia et al. Substituted dipiperidine alcohols as potent CCR2 antagonists
TW200745087A (en) CCR5 antagonists useful for treating HIV
WO2005058898A3 (en) Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
TW200640910A (en) Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
Hao et al. Human Bone Marrow Derived Mesenchymal Stem Cells And Their Released Microvesicles May Promote The Resolution Of Acute Lung Injury In Mice In Part Through Inhibition Of Multidrug Resistance-Associated Protein 1
Edwards et al. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
JP2010173956A (ja) ピロール化合物を有効成分として含有するケモカイン産生阻害剤
DOP2002000461A (es) Derivados de sulfonamida.